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 Photodynamic therapy is a relatively new player on the field of cancer treatment 
that involves the injection of a nontoxic light-sensitive drug followed by light excitation, 
creating reactive oxygen species that cause intracellular damage that ultimately brings 
about cell death. Photodynamic therapy (PDT) has the advantage over contemporary 
cancer treatment methods in that it is both non-invasive and can be tailored to largely 
avoid damage to noncancerous cells. The drawback herein is that intravenous injections 
leave most of the patients’ tissue prone to photodamage for long periods of time 
following tumor treatment. In this study, we investigated the effect of augmenting current 
photodynamic treatment methods with electroporation, a phenomenon involving passing 
an electric current through cells, known to enhance uptake of extracellular components. 
We hypothesized, therefore, that electroporating cancerous cells in the presence of 
Photofrin would increase an intracellular uptake of the photosensitizer, and would 
correlate to a higher degree of cytotoxicity in the cell lines. We conducted 
spectrophotometric intracellular concentration assays and observed a consistent and 
significant increase in intracellular Photofrin content in both MCF-7 and B16-F10 cell 
lines in those samples subjected to electroporation and an equal Photofrin concentration 
compared to the non-electroporated samples. In evaluating the cytotoxicity of 
photodynamic therapy via the clonogenic assay, we observed a significant decrease in 
cell viability in MCF-7 cells when subjected to photodynamic treatment following 
electroporation versus the non-electroporated cells at several concentrations of Photofrin. 
However, the results were not always consistent, which speaks to the nature of the cell-
based assay. What we also noticed was that although electroporation generally increased 
the intracellular Photofrin content, higher doses without electroporation yielded equal 
intracellular Photofrin, but often no significant cell death, suggesting electroporation may 
play a larger role than merely allowing Photofrin inside the plasma membrane. B16-F10 
cells, despite an increased Photofrin content after electroporation, were still unresponsive 
to PDT. Confocal imaging gave evidence of mitochondrial localization of Photofrin in 
MCF-7 cells, but an indiscernible localization in B16-F10, providing further insight into 
ePDT’s ineffectiveness with the melanoma cell line. 
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INTRODUCTION 
 
Photodynamic therapy (PDT) is a recently developed therapeutic method accruing 
much interest regarding the treatment of many forms of cancer. The process involves the 
administration of a photosensitizing drug, followed by treatment with light of a particular 
wavelength.  The preferred wavelength of light is in the red to infrared spectrum (>600 
nm), due to its proficiency at penetrating human tissue (Moore et al., 1997).  When the 
photosensitizing drug absorbs light of the appropriate wavelength, the photosensitizer is 
excited to a triplet state of electron configuration, followed by photochemical transfer to 
ground state molecular oxygen to form reactive oxygen species that can then elicit 
damage to cellular structures (Oleinick et al., 1998). 
The advantages that photodynamic therapy confers to cancer patients make it a 
potential replacement for other forms of cancer treatment. One advantageous aspect of 
photodynamic therapy is the ability to isolate its cytotoxic effect. Traditional radiation 
and chemotherapy are somewhat indiscriminate to the types of cells within the body that 
they inadvertently damage during treatment. The injected photosensitizer in 
photodynamic therapy, however, is non-toxic to cells unless excited by light within its 
absorbance spectrum to create cytotoxic oxygen radicals. Limiting light exposure to 
photosensitized noncancerous tissue is more feasible than limiting ionizing radiation or 
antineoplastic drugs to noncancerous tissue. This limiting factor to its lethal effect also 
provides somewhat of a disadvantage, as noncancerous tissue may stay photosensitized 
for up to two months (Oleinick et al., 1998).  
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 Various experiments have shown that uptake of photosensitizer has discrepancies 
between targeted tumor cells and normal tissue; for example, the ratio of Photofrin® 
uptake in mammary cancer cells to liver cells is 0.3:1 (Moore et al., 1997).  Due to this 
discrepancy, administration of photosensitizer requires a great deal of caution, as 
photoexcitation, and therefore, photosensitization associated cell damage, will occur in 
all cells containing the photosensitizer that are exposed to light.  In cells with a much 
higher uptake of photosensitizer than the targeted tumor cells, photosensitivity will be 
substantially higher. 
 To enable tumor cells to better uptake photosensitizer, electroporation of the 
tumor is being considered for eventual clinical implementation.  Electroporation involves 
stimulation of cells involving short electric, high powered pulses, which causes the 
plasma membrane to become more permeable to external agents (Powell and Weaver, 
1985).  The use of electroporation in conjunction with PDT has been shown to produce a 
much higher cytotoxic response in vitro than with PDT alone (Figure I) (Labanauskiene 
et al., 2007).  A higher uptake of photosensitizer by the tumor cells implies a lower dose 
of photosensitizer to induce desired cytotoxic effects by PDT, and consequently, normal 
cells would have less exposure to the photosensitizer. 
 The exact mechanism of how this damage is manifested may rely upon where the 
photosensitizer localizes within the cell.  Localization highly depends on the chemical 
nature of the photosensitizer: hydrophobicity, type and number of charges, charge-to-
mass ratio, type and number of ring and core constituent, and whether the uptake of the 
photosensitizer occurs by diffusion or is facilitated by endocytosis (Oleinick et al., 1998).  
Membrane localization tends to be the main effective means by which photosensitizers 
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induce their cytotoxic effects, as merely entering the cell may not allow reactive oxygen 
species, which have a short lifespan and consequently narrow effective range, to inflict 
lethal damage (Oleinick et al., 2002). 
 The cell’s fate after PDT, whether it is apoptosis, necrosis, or some other fate, is 
largely influenced by cell line, the dose of photosensitizer, dose of irradiation, incubation 
period, the particular photosensitizer, and the localization of the photosensitizer within 
the cell (Moore et al., 1997; Dellinger, 1996).  Apoptosis and necrosis are the 
predominantly observed fates of cells subjected to PDT, however cell cycle arrest and a 
process called autophagy have also been observed (Piette et al., 2003; Kessel and 
Reiners, 2007).  Cell cycle arrest generally occurs after low doses of PDT, where damage 
to microtubules could initiate the phosphorylation of anti-apoptotic Bcl-2 by CDK-1 
(Piette et al., 2003).   
 Currently, Photofrin® is the principle photosensitizer in clinical use for tumor 
treatment, and is the only photosensitizer approved for clinical use by the Food and Drug 
Administration.  As a “first-generation” photosensitizer, it poses many problems which 
make it less than optimal, including its inefficient absorbance at wavelengths of light at 
>600nm (Figure II), its chemical complexity, and its effect of making patients 
photosensitive for 1-2 months after treatment (Moore et al., 1997; Oleinick et al., 1998; 
Piette et al., 2003).  However, because it is the only FDA-approved photosensitizer, it has 
been widely studied and is most likely to achieve a more immediate diversified 
application. 
 In this study, we focused on two cancer types that could potentially benefit from 
the implementation of photodynamic therapy: breast cancer and melanoma. Breast cancer 
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affects one in eight women and often requires surgical lumpectomy, and in some cases a 
complete mastectomy (Solomayer et al., 2000). Photodynamic therapy provides an 
alternative to the noninvasive options of radiation and chemotherapy, with potentially 
fewer deleterious side effects. In this study, we used the MCF-7 human epithelial breast 
cancer cell line, a weakly invasive metastatic cell line taken from a biopsy of a 69 year 
old Caucasian woman, that like most breast cancer expresses estrogen receptors, as an in 
vitro analog (Lacroix and Leclercq, 2004). Melanoma results from uncontrolled 
proliferation of melanocytes, melanin-producing skin cells, that is the leading cause of 
death from skin disease. In all current cases of melanoma, surgical removal is required, 
making a localized noninvasive procedure such as photodynamic therapy a welcomed 
alternative (Markovick et al., 2007). Furthermore, the superficial location of melanoma 
provides a greater ease with which to apply greater energies of light involved in 
photodynamic therapy. B16-F10 mouse melanoma cells provided the in vitro analog in 
this study.  
 Previous research in our lab has demonstrated an effectiveness of photodynamic 
therapy on MCF-7 cells, with additional cell death when assisted with electroporation 
(Figure III). These results also indicate increased effectiveness as length of light exposure 
increases. B16-F10 melanoma cells, however, were not observed to undergo the same 
cytotoxic effects of photodynamic therapy as the MCF-7 cells (Figure V). Odd, however, 
was the observation that Photofrin alone in higher doses reduced cell viability (Figure 
IV). As photosensitizers used in photodynamic therapy are nontoxic, cell death should 
not have been observed with these treatments (Moore et al, 1997). A potential fault in 
these findings may have been the viability assay used. The MTT assay used in our lab’s 
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previous studies is based on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to non-water-soluble formizan crystal by 
metabolically active cells. The shortcoming of this assay is that it  provides a relatively 
short-term ascertainment of cell viability. Xue et al. made an observation that apoptosis 
was not initiated in Pc 4 photodynamic therapy of MCF-7 cells until 24 hours after 
treatment, enforcing the notion that an assay measuring long-term viability is needed to 
discern an effective cytotoxicity and be an accurate predictor of behavior of cancerous 
cells in vivo (Xue et al., 2001). Therefore, in the current study we ascertained the viability 
of MCF-7 cells and B16-F10 cells post-photodynamic treatment with the clonogenic 
assay in order to determine trends of cell viability we had seen with the short-term MTT 
assay, and potentially determine an effectively lethal Photofrin and light dose. 
 Furthermore, we wanted to assess an intracellular localization of Photofrin in both 
MCF-7 and B16-F10 cell lines. A possible explanation for the ineffectiveness of 
photodynamic treatment of B16-F10 cells in the previous study was an aversion of these 
cells to uptake Photofrin. Consequently, we needed to establish a correlation between the 
amount of Photofrin MCF-7 cells were able to uptake and their observed mortality. 
Numerous studies have determined uptake and intracellular localization of 
photosensitizers via confocal imaging and/or fluorometric or spectrophotometric analyses 
(Chwilkowska et al., 2003; Kramer-Marek et al., 2005; Marchal et al.,2007; Tamosiunas 
et al., 2005; Woodburn et al., 1998). In this study, we chose to assess the intracellular 
uptake of Photofrin via spectrophotometric absorbance. We chose to further explore 
specific subcellular localization of Photofrin within MCF-7 and B16-F10 cells through 
confocal imaging.  
MATERIALS AND METHODS 
 
Cell Culture 
 Both MCF-7 and B16-F10 cell lines were cultured at 37oC, 5% CO2 in RPMI 
1640 medium containing 2.1 mM L-glutamine and phenol red, supplemented with 10% 
fetal bovine serum, 10 µg/ml insulin, and10 µg/ml gentamicin (RPMI complete medium). 
Cells were passaged by performing 5 minute incubation at 37oC, 5% CO2 with 0.1% 
trypsin, then harvested by centrifugation and reseeded into the appropriate vessel. 
 
Intracellular Photofrin Concentration 
 All work was done illuminated by a 60 W incandescent bulb filtered by a red 
fabric in order to reduce incident light potentially exciting Photofrin before light 
treatment. 
Cells were removed from flasks via trypsinization, centrifuged, and resuspended 
in RPMI complete medium. Cells were counted using a hemocytometer with trypan blue 
exclusion, then diluted to 1.3*106 cells/ml for a final treatment concentration of 1.0*106 
cells/ml. This cell suspension was placed into either 2.5 ml microcentrifuge tubes or 4mm 
gap electroporation cuvettes, followed by the addition of a 100µg/ml Photofrin solution 
in Phosphate Buffered Saline (PBS). The microcentrifuge tubes were allowed to incubate 
at 37oC, 5% CO2 for 10 minutes, immediately followed by centrifugation. The cuvettes 
were electroporated at 100V with five 1ms pulses and immediately placed on ice for 10 
minutes. Contents of the cuvettes were transferred to microcentrifuge tubes and 
centrifuged. All samples were washed with PBS, centrifuged, and resuspended in 400 µl 
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methanol. Samples were placed on ice and a sonicator was applied for 2 minutes to 
mechanically disrupt the cell membrane, then centrifuged. The supernatant was 
transferred to new microcentrifuge tubes and centrifuged again to remove remaining 
debris. Samples were placed in 100 µl aliquots into a 96-well plate and the absorbance of 
each well was read at 405 nm.  
 Intracellular concentration was also measured after timed incubation with 
Photofrin. Cells were harvested as previously described, diluted to 4.0*105 cells/ml for a 
final treatment concentration of 2.0*105 cells/well. This cell suspension was placed in 
wells of a 6-well plate in a 2 ml final volume of RPMI complete medium with added 
solution of 1mg/ml Photofrin in PBS for a final concentration of 12.5 µg/ml or 50 µg/ml 
Photofrin. The plates were placed in a light-resistant box, which was placed in an 
incubator at 37oC, 5% CO2, and allowed to incubate for 12, 24, or 48 hours. Following 
the incubation period, the wells were washed with PBS and trypsinized, followed by 
centrifugation. The cell pellet was washed again with PBS, centrifuged, and resuspended 
in 400µl methanol. This suspension was sonicated and read spectrophotometrically as 
mentioned previously. 
 
Clonogenic Assay 
All work was done illuminated by a 60W incandescent bulb filtered by a red 
fabric.  
Cell survival after electroporation-assisted photodynamic treatment was 
determined by clonogenic assay. Cells were harvested and counted as previously 
described, and diluted to 8.3*105 cells/ml, giving a final treatment concentration of 
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6.5*105 cells/ml. Cell suspension was placed into a 2.5 ml microcentrifuge tube or 4mm 
gap electroporation cuvette and incubated or electroporated while exposed to 0, 6.25, 
12.5, 25, 50, or 100 µg/ml Photofrin, and centrifuged as described previously. Cells were 
resuspended in PBS and diluted to 5,000 cells/ml and plated in wells of a 6-well plated at 
500 cells per well in 2ml of RPMI complete medium. Each well received light treatment 
using a 635 nm laser at 20mW, lasting 60, 120, 180, 240, 300, or 360 seconds, followed 
by an incubation period of between 5 and 10 days. Following the incubation period, the 
medium was removed and a solution of 6% gluteraldehyde, 0.5% crystal violet was 
applied to each well, fixing and staining resulting colonies. This solution was removed 
and the wells were rinsed and allowed to dry. Surviving colonies were then counted 
under a microscope.  
 
Confocal Imaging 
 Cells were harvested from approximately 90% confluent flasks via trypsinization. 
Cells were diluted to 1.0*106 cells/ml and incubated with 25 µg/ml Photofrin for 10 
minutes at 37oC, 5% CO2 in RPMI complete medium. Cells were centrifuged, 
supernatant was removed, cells were washed with PBS, centrifuged again, and 
resuspended in RPMI complete medium. Cells were allowed to incubate for 30 minutes at 
37oC, 5% CO2 with 200 nM MitoTracker Deep Red or 20 µg/ml acridine orange. Cells 
were then centrifuged, washed with PBS, resuspended in RPMI complete medium, and 
transported to the microscope in a dark container. Cells were plated on a depression slide 
and imaged with a Carl Zeiss LSM 510 laser scanning microscope. Cells were 
illuminated with a 488 nm laser to view cells stained with acridine orange and Photofrin. 
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Images were captured using a long pass filter attenuating wavelengths shorter than 505 
nm for one channel, and a band pass filter transmitting light between the wavelengths of 
505 and 560 nm captured a second channel. For cells stained with Photofrin and 
Mitotracker, long pass filter attenuating light of wavelengths shorter than 585 nm was 
used. Mitotracker localization was determined via illumination with a 633 nm laser, and 
Photofrin localization was determined via illumination with a 543 nm laser. 
RESULTS 
 
Intracellular Photofrin Concentration 
 Cell membranes were sonically broken and the cytosolic contents read 
spectrophotometrically to confirm the uptake of Photofrin into the cell, and to verify an 
increased uptake with Photofrin exposure in conjunction with electroporation. MCF7 
cells showed a significant (P<0.05) uptake of Photofrin versus both the control and the 
electroporated control at all doses tested (Figure 1). When exposed to 12.5 µg/ml 
Photofrin, there was not a significant increase in the Photofrin uptake when 
electroporated vs. the non-electroporated control; however, a significant increase in 
Photofrin uptake was observed when electroporated while exposed to 25, 50, and 100 
µg/ml Photofrin, compared to the non-electroporated treatments. 
 B16-F10 cell treatments showed similar results to the MCF-7 cell treatments, as 
all doses of Photofrin exhibited a significant uptake (Figure 2). There was a significant 
increase observed with the electroporated 12.5 µg/ml treatment versus the non-
electroporated that was not observed in MCF-7s. Additionally, an increased Photofrin 
uptake was observed with the electroporated samples with the 25, 50, and 100 µg/ml 
exposures versus the non-electroporated samples, as was seen in the MCF-7 samples.  
Figure 3 illustrates the measured Photofrin content of MCF-7 and B16-F10 cells 
after 12, 24, and 48 h incubations with Photofrin without electroporation. When 
incubated with 12.5 µg/ml Photofrin, both MCF-7 and B16-F10 samples showed a 
relatively unchanged uptake between the three incubation periods, with the MCF-7s 
retaining slightly more than 0.2 pg per cell, and the B16-F10s retaining slightly less. 
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Incubation with 50 µg/ml Photofrin showed greater variation between incubation periods, 
with an increase in Photofrin uptake and retention in both MCF-7 and B16-F10 samples 
after a 48 h incubation versus both the 12 and 24 h incubation uptake levels. 
 
Photofrin Dose Response 
 Initially, MCF-7 cells were treated with varying doses of Photofrin with a 
consistent 180 s light treatment with a 20 mW, 635 nm laser, giving a total fluence of 
37.4 J/m2.  When exposed to Photofrin only, without electroporation or exposure to light 
(Figure 4), there was no significant decrease in the number of viable colonies counted in 
the clonogenic assay with any of the samples exposed to up to 25 µg/ml Photofrin. When 
exposed to up to 25 µg/ml Photofrin followed by light treatment (Figure 5), MCF-7 cells 
continued to show no significant decrease in cell viability. MCF-7 cells exposed to only 
Photofrin and electroporation (Figure 6) showed no significant decrease in cell viability 
even with Photofrin exposure concentrations as high as 100 µg/ml. The only significant 
decrease in cell viability at the administered concentrations of Photofrin could be seen 
when cells were exposed to Photofrin and electroporated, followed by laser treatment.  
As shown in Figure 7, a concentration of 12.5 µg/ml was the lowest administered 
concentration of Photofrin yielding a significant decrease in cell viability, approximately 
50% of the control viability. The higher doses, 25 and 100 µg/ml Photofrin also showed 
significant decrease in cell viability (26% and 19%, respectively). The samples treated 
with 6.25 µg/ml Photofrin showed no significant decrease in cell viability.  
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Light Dose Response 
As the 12.5 µg/ml treatment concentration of Photofrin resulted in a significant 
decrease in cell viability, MCF-7 and B16-F10 cells were subjected to Photofrin exposure 
with electroporation, followed by light treatment (this combined treatment referred to 
hereafter as ePDT) with the same 20 mW, 635 nm laser for additional lengths of time 
ranging from 60 s to 360 s. When exposed to the light treatment alone, there was no 
significant decrease in cell viability between 60 s and 240 s with the MCF-7 samples, 
versus the control samples (Figure 8). In the following figures (Figures 9-12), the 
samples receiving only light exposure were used as controls. When treated with 60 s of 
light (Figure 9), both the samples exposed to only Photofrin and light (this treatment 
referred to hereafter as PDT) and ePDT samples showed significant decrease in cell 
viability, however, the ePDT sample did not show considerably less viability than the 
PDT sample (roughly 80%). With the samples treated with 120 s of light (Figure 10), the 
ePDT sample was the only sample with significant decrease in cell viability from the 
control, resulting in 71% survival. This sample also showed significantly less survival 
than the PDT sample’s approximate 87% survival. Treatments with 180 s (Figure 11) also 
showed a significant decrease in viability between the control and ePDT samples (66% 
viability), however, there was no difference between the ePDT electroporation, Photofrin, 
and light treatment sample’s and PDT the Photofrin and light treatment only sample’s 
survival. When exposed to 240 s (Figure 12), there were no significant decreases in cell 
viability from the control. 
 Experiments were repeated for 60 s and 120 s timed light exposure, and an 
additional exposure time of 300 s was performed. When exposed to these timed 
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exposures, electroporation resulted in no decreased cell viability from the light exposure 
only (Figure 13), reinforcing previous data (figures 6, 7, 12) that indicated that 
electroporation alone was not lethal. When repeated with these timed exposures, the 
ePDT treatments showed significant decrease in cell viability from the PDT treatments 
with the 120 s and 300 s light exposure (74% and 75%, respectively), however, there was 
no decrease in cell viability with the 60 s light exposure as had been observed in the 
earlier experiments (Figure 9).  
 B16-F10 murine melanoma cells were subjected to identical experiments using 
12.5 µg/ml Photofrin with varying light doses as the MCF-7 cells, with an additional 
timed light exposure of 360 s. Clonogenic assay data from the treatment with 60 s of light 
exposure (Figure 15) showed no decrease in cell viability with electroporation alone, nor 
with PDT or ePDT. The 120 s light exposure treatment also showed no decrease in cell 
viability for the electroporated samples, or the samples treated with PDT or ePDT (Figure 
16). The PDT and ePDT samples treated with 180 s of light exposure also showed no 
decrease in cell viability, however, there was an isolated anomalous decrease in cell 
survival with the samples treated only with electroporation and light (Figure 17). 
Treatment with 240 s of light exposure yielded no difference in cell viability between the 
electroporated, PDT, and ePDT samples (Figure 18); however, these samples did show 
significant decrease in cell viability from the control. Timed light exposures were 
extended to include 300 and 360 s (Figures 19, 20), resulting in similar observations of 
no decrease in cell viability between samples treated with electroporation and light only, 
PDT, or ePDT. Experiments were repeated with light exposure times of 60, 240, and 300 
s. When exposed to 60 s light (Figure 21), there was no decrease in cell viability with 
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electroporation, PDT, or ePDT as previously demonstrated (Figure 15). Results were 
similar with the repeated experiment with 240 s of light exposure (Figure 22), as there 
was no decrease in cell viability with electroporation, PDT, or ePDT versus the control. 
The repeated experiment with light exposure time of 300 s also mirrored the initial results 
of no decrease in cell viability with electroporation alone, PDT, or ePDT (Figure 23). 
 
Subcellular Localization 
 MCF-7 cells were imaged while co-stained with Photofrin and either nucleic acid 
specific dye Acridine Orange or mitochondrial dye MitoTracker Deep Red. Images taken 
with AO stained cells (Figure 24) excited with 543 nm laser and filtered for wavelengths 
above 525 nm (green to red) showed nuclear localization with some cytosolic presence, 
along with lysosomal localization. When MCF-7 cells were imaged with Photofrin alone 
(Figure 25), most fluorescence was observed in the cytosol with brighter fluorescence 
around unidentifiable organellar membranes. Staining with both AO and Photofrin 
(figure 26) showed  primarily cytoplasmic fluorescence when filtered to transmit 
wavelengths longer than 505 nm (Figure 26.a), and showed primarily nuclear 
fluorescence when filtered to transmit only wavelengths between 505 and 560 nm (figure 
26.b). The band pass filter between 505 and 560 nm was used to isolate the emission peak 
of AO and the long pass filter (λ>505) was used to capture the emission peak of Photofrin 
(610 nm). As AO displays emission peaks at both 525 and 650 nm, and has excitation and 
emission spectra which overlap with those of Photofrin, fluorescence due to AO was 
observed with both filters and Photofrin localization could not be specifically observed 
using this method. Using MitoTracker Deep Red, which has an excitation maximum at 
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644 nm, far above Photofrin’s excitation maximum of 396 nm, images were captured 
using a long pass filter (λ>585 transmitted) and different lasers were used for excitation 
of each fluorophore (633 nm for MitoTracker and 543 nm for Photofrin) (Figure 27). 
Figure 27.a shows the channel for MitoTracker, displaying bright fluorescence among the 
mitochondria. Using a lower excitation wavelength, Photofrin was excited and the 
fluorescence was again observed primarily in the cytosol, with some localization to 
organelles (Figure 27.b).  Transposing the two channels reveals an overlap between 
Photofrin’s organellar localization observed in figure 27.b and the MitoTracker’s 
fluorescence observed in 27.a, suggesting mitochondrial localization of Photofrin in 
MCF-7 cells; however, not all cells observed displayed the same mitochondria-associated 
fluorescence with the Photofrin specific excitation, as seen in Figure 28. 
 B16-F10 cells were exposed to Photofrin and imaged using an excitation 
wavelength of 543 nm and filtered using a long pass 585 filter. Images showed primarily 
cytosolic localization of Photofrin within the cell, with some fluorescence observed 
within the nucleus, but no other organellar localization was observed, as was in MCF-7 
cells. 
 
DISCUSSION 
 
 Previous work in our lab has shown the effectiveness of augmentation of 
photodynamic therapy with electroporation with MCF-7 and B16-F10 cell lines. In this 
study, we sought to further explore the effectiveness of this treatment, as well as 
determine the concentration and intracellular localization of Photofrin. The initial uptake 
and intracellular amount of Photofrin was shown to increase under two conditions.  First, 
with an increase in Photofrin concentration without electroporation and secondly, when 
electroporated while exposed to the same Photofrin concentration. Ultimately, we were 
able to confirm earlier results within the laboratory suggesting an increased efficacy of 
PDT when assisted with electroporation in the MCF-7 cell line. Prior experiments in the 
laboratory were unsuccessful in showing significant effectiveness of ePDT in the B16-
F10 cell line.   With our current parameters we were able to determine further that, PDT 
does not seem to significantly induce cytotoxic effects in this cell line. Confocal imaging 
enabled us to further explore the observed cytotoxicity of Photofrin, as it suggested a 
subcellular localization of the photosensitizer to MCF-7 mitochondria, however, there 
was no discernable subcellular localization of Photofrin to B16-F10 organelles.  
 
Intracellular Photofrin 
Intracellular Photofrin content of MCF-7 and B16-F10 cell lines was determined 
by spectrophotometric absorbance at 405 nm, near Photofrin’s maximum absorbance of 
396 nm, of the resultant supernatant of the cells’ sonication in methanol after incubation 
with Photofrin with and without electroporation. This method allowed for the release of 
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cytoplasmic contents via physical membrane disruption as well as the solubility of the 
lipid plasma and organellar membranes in methanol. Confirming levels of Photofrin 
within the cells gave evidence towards Photofrin being the causality of any observed 
reduction in cell viability. Furthermore, determining increased intracellular levels of 
Photofrin after electroporation during exposure to the photosensitizer gave confirmation 
that electroporation indeed does increase the amount of Photofrin cells are able to uptake 
(Figures 1, 2), enabling a correlation to be established between amount of Photofrin 
entering the cells and their viability. It was also important to establish that despite the 
absence of cell death previously observed with B16-F10 cells that there was, in fact, 
Photofrin entering the cell. Determing kinetic uptake provided some insight into the 
relative uptake of Photofrin in MCF-7 and B16-F10 cell lines (Figure 3). In both cell 
lines exposed to 12.5 µg/ml Photofrin, there was no discernable trend in uptake. 
However, when exposed to 50 µg/ml, both cell lines exhibited an increase between 12 h 
and 48 h incubations. This result conflicts with data obtained by Chwilkowska, et al., 
who observed a maximum uptake of Photofrin in MCF-7 cells after a 24 h incubation, 
followed by a decrease of intracellular Photofrin (Chwilkowska et al., 2003). The kinetic 
uptake results obtained in this study were conducted singly and cannot be statistically 
evaluated. They do, however, suggest an increase in cellular uptake of Photofrin after 
prolonged incubations. While this study suggests prolonged exposure to Photofrin 
increases its intracellular concentration, it also confirms electroporation’s effect of 
increasing intracellular Photofrin nearly two-fold (in 25 and 50 µg/ml doses), further 
suggesting a more expedient light treatment after clinical administration of Photofrin. 
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Effectiveness of ePDT 
 In the current study, in the MCF-7 cell line we saw a significant reduction in cell 
viability to approximately 50% using electroporation during exposure to a Photofrin dose 
of 12.5 µg/ml and using 180 s of a 20 mW red laser exposure (Figure 7), versus no 
reduction in cell viability using only Photofrin and light exposure (Figure 5). These 
results reinforce previous findings in our lab, which show a similar trend with cell 
viability levels reaching 20% when electroporated versus 80% with PDT without 
electroporation (Figure III). Further treatments in this study (Figures 9-12) resulted in 
70% cell viability: a lower treatment effectiveness, but consistently more effective than 
Photofrin and light alone.  
Discrepancies between our lab’s previous results and the less effective 
photodynamic therapy treatment observed in this study could be attributed to the method 
in which cell viability was ascertained. The MTT assay was used to determine cell 
viability in our lab’s previous study. Although the MTT assay is a method enabling 
convenient succession of multiple experiments, it has been found to provide only 77.8% 
true-negative results versus the clonogenic assay (Shimoyama et al., 1989) and no 
significant correlation with the clonogenic assay when observing chemosensitivity to 
some anti-cancer agents, such as vinca alkaloids, etoposide, irinotecan, and rhizoxin on 
human lung cancer cell lines (Kawada et al., 2002). Furthermore, Xue, et al. have 
demonstrated through chromatic shrinkage and fragmentation that apoptosis occurs in Pc-
4 mediated photodynamic therapy in MCF-7 cells 24 hours after the treatment, increasing 
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the need for assays measuring cell viability at longer terms than MTT (Xue et al., 2001). 
Determining the effectiveness of electroporation assisted photodymanic therapy with the 
clonogenic assay in this study confirmed previously observed cell death determined by 
MTT, but not at the levels previously obtained, potentially due to the MTT assay’s lower 
accuracy. Our results indicated that the clonogenic assay also showed that no cytotoxic 
effect was observed with Photofrin exposure alone at doses of even 100 µg/ml, versus a 
cell survival of approximately 50% shown with MTT (Figure IV). Effectiveness of the 
treatment was observed to increase with increasing concentration of Photofrin (Figure 7), 
however, using the lowest effective dose combined with increasing light doses did not 
yield increased cell death as had previously been seen, with a minimum cell viability of 
66% at 180 s of light exposure versus a reduction to nearly 20% viability at 240 s in the 
previous study.  
  Although the effect of the electroporation assisted photodynamic therapy proved 
somewhat limited with MCF-7 cells, it proved practically absent with the B16-F10 line. 
Our lab’s previous results showed no significant reduction in cell viability with B16-F10 
cells using a Photofrin dose of 6 µg/ml up to 200 s of light exposure (Figure V). This lack 
of effectiveness was echoed in the current study even with a doubled Photofrin dose of 
12.5 µg/ml and up to 360 s of light exposure (Figure 20).  
 
 
Effectiveness of ePDT on MCF-7 
 In this study, there was a clear correlation between the PDT’s effectiveness with 
electroporation and a resultant decrease in MCF-7 cell viability. There have been studies 
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on the mechanisms of MCF-7 cells’ response to PDT with various photosensitizers, 
including Photofrin. In the MCF-7 cell line, Photofrin has been found to initially localize 
to the inner side of the plasma membrane, and after a 4-hour incubation, localize to the 
nuclear envelope and cellular compartments around the nucleus, presumably the 
mitochondria, with a maximum Photofrin uptake after a 24-hour incubation 
(Chwilkowski et al., 2003; Saczko et al., 2007). Other photosensitizers have shown 
preferential localization to other organelles within MCF-7 cells, such as Foscan’s 
localization to the Golgi apparatus and the endoplasmic reticulum (Marchal et al., 2007) 
and NPe6’s preferential localization to lysosomes (Usuda et al., 2008) in MCF-7 cells. 
Usuda et al. found that Photofrin mainly localizes to the mitochondria and damages Bcl-
2, an anti-apoptotic protein, whereas NPe6 localizes to the lysosome and does not 
damage Bcl-2, resulting in less reduction in cell viability, underlining the principle that 
different photosensitizers induce cell death via different pathways to which MCF-7 cells 
are susceptible. What was observed in this study via confocal imaging was a specific 
localization of Photofrin to mitochondria (Figure 27) and diffusion throughout the 
cytoplasm and within the nucleus (Figure 28), suggesting that the cell death observed in 
this study was obtained by the pathways described in previous studies, namely through 
the damage of Bcl-2. Figures 27 and 28’s dissimilarities in localization may indicate a 
kinetic localization or kinetic efflux associated with Photofrin’s activity within MCF-7 
cells. 
Interestingly, intracellular levels of Photofrin observed in electroporated cells 
exposed to 12.5 µg/ml Photofrin were identical to those levels observed in non-
electroporated cells exposed to 25 µg/ml, and less than intracellular levels observed in 
  
21 
 
 
 
non-electroporated cells exposed to 50 and 100 µg/ml Photofrin (Figure 1); however, 
these latter, non-electroporated samples with higher content of intracellular Photofrin 
showed no decrease in cell viability, whereas the electroporated sample exposed to 12.5 
µg/ml did show decreased cell viability. Although the content of Photofrin is identical in 
both samples, the PDT is more effective when combined with electroporation. As Usuda, 
et al. described, Photofrin may achieve its cytotoxic effect primarily from damaging the 
anti-apoptotic protein Bcl-2. The subcellular localization of Bcl-2 has traditionally been 
believed to be on the outer membrane of the mitochondria (Jun et al., 2007), however, 
there is other evidence that Bcl-2 predominantly localizes to the inner mitochondrial 
membrane (Gotow et al., 2000). A better access to the inner mitochondrial membrane, 
and therefore more Bcl-2, could potentially explain this study’s observed higher 
effectiveness of PDT on electroporated cells, despite a similar intracellular content of 
Photofrin in the non-electroporated cells. Supra-electroporation is a method of passing a 
current through cells involving 10 to 300 kV/cm with pulses less than 1 µs, which is 
believed to open channels in organellar membranes rather than only opening channels in 
the plasma membrane achieved by conventional electroporation, which involves 0.1 to 1 
kV/cm and pulses of more than 100 µs (Gowrishankar et al., 2006). However, one study 
provides a model which suggests that conventional electroporation can result in 
secondary transmembrane voltages that could open channels within organellar 
membranes (Esser et al., 2010). Using conventional electroporation with a field of 0.25 
kV/cm with 1 ms pulses, as done in the electroporation in this study, could potentially 
cause these organellar channels to open, particularly effective in the mitochondria, 
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resulting in a larger amount of Photofrin reaching the inner mitochondrial membrane, and 
therefore damaging more Bcl-2 localized to this inner mitochondrial membrane.  
 
Unresponsiveness of B16-F10 
 There are obviously different responses to Photofrin mediated electroporation 
assisted photodynamic therapy in MCF-7 and B16-F10 cells. Data from this study 
(Figures 1, 2) suggests that B16-F10 cells are able to uptake and retain 0.003 ng 
Photofrin per cell with a 12.5 µg/ml Photofrin exposure with electroporation, surpassing 
the retention of MCF-7 cells (0.002 ng/cell) with the same treatment, which was observed 
to elicit cytotoxic effects with photodynamic therapy. However, even with a slightly 
higher uptake than the lethal level observed in MCF-7 cells, B16-F10 cells remain viable 
after photodynamic therapy. One explanation for this continued viability is the melanin 
content of the B16-F10 cells. Melanin’s primary function is to prevent much of the light 
of wavelengths that coincide with the excitation of Photofrin from penetrating the cell, 
resulting in a decreased effectiveness of PDT with cancers such as melanoma (Peeva et 
al., 1999). Not only does melanin serve to decrease the amount of permeating light, but it 
also has been found to effectively scavenge reactive oxygen species such as those critical 
for PDT’s cytotoxic effects (Lim et al., 2004). However, PDT in B16-F10 cells has been 
effective with photosensitizers with a much stronger absorbance in the near infrared 
wavelengths or with a much broader absorbance spectrum than Photofrin (Woodburn et 
al., 1998; Lim et al., 2004).  
Another limitation of this study’s effectiveness with B16-F10 treatment is the 
wavelength of light treatment. Red light, used for this study, penetrates deeper into tissue 
  
23 
 
 
 
than other wavelengths of light. However, melanoma is generally located superficially, 
requiring less penetration than deeper tumors. Therefore, a light dose of a shorter 
wavelength could potentially be clinically applied. Light with shorter wavelength and 
higher energy has been shown to elicit greater cytotoxicity in B16-F10 cells with 
Photofrin, lowering the dose required to achieve 50% viability by half (Menezes et al., 
2007).  
Subcellular localization of Photofrin within the cell has proven to play a major 
role in eliciting ultimately cytotoxic cell damage, due to the short lifespan of reactive 
oxygen species formed after photosensitizer excitation, resulting in a very short migration 
of less than 0.2 µm (Oleinick et al., 2002). Confocal imaging of B16-F10 cells with 
Photofrin provided little insight into the specific localization and potential pathway for 
cell death through effective PDT. Most fluorescence from Photofrin in B16- F10 cells 
comes from seemingly non-specific dispersion throughout the cytoplasm, as well as some 
nuclear localization (Figure 29). Photofrin PDT has been shown to cause some damage to 
nuclear DNA, but this damage does not result in cell death, as the oxidative damage 
caused is usually repaired by base excision mechanisms (Woods et al., 2004). A 
nonspecific localization of Photofrin in B16-F10 cells does not make B16-F10 a 
promising candidate cell line for Photofrin PDT. 
The affinity for hematoporphyrins, such as Photofrin, for lipoproteins has been 
observed and exploited for use in delivery of cytotoxic agents to cancerous cells, 
including Photofrin to MCF-7 cells in vitro, and elliptinium olleate in B16 melanoma in 
rabbit models (Somadi-Baboli et al., 1993; Chwilkowska et al., 2003). It has also been 
noted that in mice, high-density lipoproteins (HDL) are the chief transporters, whereas in 
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humans, the low-density lipoproteins (LDL) prevail (Woodburn et al., 1998). It has been 
shown that when Photofrin is coupled with LDL, resulting retention of Photofrin in 
human fibroblasts is much higher than that of those exposed to Photofrin coupled with 
HDL or albumin (Candide et al., 1986). B16 melanoma has also been shown to have LDL 
receptors with great affinity for LDL internalization and LDL analog, apolipoproteinE-
containing liposomes coupled with anticancer agent daunorubicin both in culture and in 
vivo (Versluis et al.; 1996, 1998). However, the human cells’ affinity for LDL-mediated 
transport may provide an advantage to effective Photofrin delivery and account for a 
slightly higher Photofrin retention at doses of 50 and 100 µg/ml observed in this study 
(Figure 1, 2). 
CONCLUSION 
 
The data presented in this study confirms an enhanced efficacy of Photofrin-
mediated photodynamic treatment of MCF-7 cells when assisted with electroporation. 
This enhanced efficacy correlates to an increased amount of observed intracellular 
Photofrin when electroporated during exposure compared to non-electroporated cells. 
Although there is a similar increase in intracellular Photofrin with electroporated B16-
F10 cells versus non-electroporated cells, there is no correlating decrease in cell viability. 
This was to be expected, as the B16-F10 cell line has proven nearly impervious to 
photodynamic therapy with most photosensitizers, including Photofrin, in numerous 
studies, including our lab’s previous findings with the MTT assay. The B16-F10 line 
provides several impediments for effective PDT, including its melanin content and 
indeterminate subcellular localization. We have seen in this study, and it has been 
confirmed in others, the specific localization of Photofrin to MCF-7 mitochondria, which 
has implications towards the specific pathway of the initiation of apoptosis conferred by 
Photofrin mediated PDT. B16-F10 cells, however, showed mostly diffusion throughout 
the cytoplasm in this study, implying indiscriminate, and ultimately non-lethal, reactivity 
of oxygen radicals generated during Photofrin excitation.  
Cytotoxicity in MCF-7 cells was also demonstrated in this study to correlate with 
an increase in concentration of Photofrin exposure when electroporated. Although higher 
Photofrin doses prove to yield a greater lethality, caution should be taken in ultimately 
establishing a treatment dose clinically, as non-tumor cells are also prone to the lethal 
effects of photosensitizers. This study further supports that electroporation potentially 
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provides an effective means to augment clinical Photofrin-mediated photodynamic 
therapy in breast cancer, by enhancing photosensitizer uptake and potentially influencing 
subcellular localization to coerce apoptotic initiation. In a study conducted by 
Tamosiunas, et al., in vivo application of electroporation assisted photodynamic therapy 
was conducted on hepatoma tumors in mice with the photosensitizers aluminum 
phthalocyanine and chlorine e6, describing similar results of increased uptake of 
photosensitizer within cells of the electroporated tumors; in this study, however, they 
observed no increased photosensitivity of the tumors (Tamosiunas, et al., 2005). 
However, a greater selectivity of the photosensitizers to the tumor was observed, 
suggesting, as does our current study, that Photofrin would likely preferentially target 
tumor cells that have been electroporated, reducing the amount of Photofrin exposed to 
non-tumor cells, and therefore reducing overall photosensitivity in patients receiving 
PDT. Photodynamic treatments of melanotic melanomas, such as B16-F10 cells, on the 
other hand, will require more modifications to induce an effective cytotoxic response. 
FUTURE RESEARCH 
 
 Work is currently being conducted by our lab to illustrate a dose response of B16-
F10 cells to Photofrin, as the conducted 12.5 µg/ml treatments elicited no significant 
decrease in cell viability, even when electroporation resulted in increased uptake. Also, 
further fluorescent imaging is underway to determine whether subcellular localization of 
Photofrin following electroporation or with higher doses is altered in the MCF-7 and 
B16-F10 cell lines. While Photofrin may be observed to localize to the mitochondria in 
both electroporated and non-electroporated cells, comparison of Bcl-2 damage by 
western blotting should be conducted to determine the method of apoptosis in 
electroporation-assisted PDT treatment. As lipoprotein coupling and internalization may 
also play a role in uptake of photosensitizer, and may account for the differences in 
cytotoxicity between MCF-7 and B16-F10 cells, an investigation of Photofrin’s affinity 
for both HDL and LDL should be performed, as well as relative measurements of the 
affinity of MCF-7 and B16-F10 cells for HDL and LDL. As PDT is already being used 
clinically to treat tumors, future research should also focus on further in vivo and clinical 
application of locally injected photosensitizer combined with local electroporation. 
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Figure I: Effect of electroporation of DC-3 Chinese hamster lung fibroblast cells with 
chlorine e6-mediated PDT on cell viability (Labanauskiene et al., 2007). 
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Figure II: Absorbance (max 396 nm) and emission (max 625 nm) spectra of  
Photofrin (---). (Pottier et al., 1985) 
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Figure III: MTT survival assay of MCF-7 cells treated with 6 ug/ml Photofrin with a 10 
minute incubation, with or without electroporation of five 1 ms pulses at 100 V, treated 
with a 635 nm laser at 20 mW for the indicated time period. (Jenna Bone) 
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Figure IV: MTT survival assay of MCF-7 cells treated with indicated concentration of 
Photofrin with a 10 minute incubation without electroporation or light treatment. (Jenna 
Bone) 
  
32 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
20 40 70 130 200
Light Exposure (s)
Ab
so
rb
an
ce
 
 
.
 
 
Figure V: MTT survival assay of B16-F10 cells exposed to 6 ug/ml of Photofrin with a 
10 minute incubation, followed by electroporation with five 1 ms pulses of 100 V and 
exposed to a 635 nm laser at 20 mW for the indicated time. (Jenna Bone) 
 
  
33 
 
 
 
 
 
Figure 1:  Photofrin content of MCF-7 cell lysates in methanol, following exposure to 
Photofrin with or without electroporation. Error bars represent standard error 
of the mean content of triplicate readings. * : difference between indicated 
samples statistically significant (P≤0.05). † : difference between indicated 
samples not statistically significant (P>0.05). 
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Figure 2:  Photofrin content of B16-F10 cell lysates in methanol, following exposure to 
Photofrin with or without electroporation. Error bars represent standard error 
of the mean content of triplicate readings. * : difference between indicated 
samples statistically significant (P≤0.05). † : difference between indicated 
samples not statistically significant (P>0.05). 
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Figure 2b: Comparison of Photofrin content of B16-F10 and MCF-7 cell lysates in 
methanol, following exposure to Photofrin with or without electroporation. 
Error bars represent standard error of the mean content of triplicate readings. 
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Figure 3:  Photofrin content of cells following a 12, 24, or 48 incubation period exposed 
to 12.5 or 50 µg/ml Photofrin. 
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Figure 4:  Surviving MCF-7 colonies after treatment with 6.25, 12.5, and 25 µg/ml 
Photofrin, without electroporation or light treatment. Error bars represent 
standard error of the mean of surviving colonies of triplicate experiments. * : 
difference between indicated sample and control is significant (P≤0.05).  
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Figure 5:  Surviving MCF-7 colonies after treatment with 6.25, 12.5, and 25 µg/ml 
Photofrin, without electroporation, exposed to 180 s of 635 nm light at 20 
mW. Error bars represent standard error of the mean of surviving colonies of 
triplicate experiments. * : difference between indicated sample and control is 
significant (P≤0.05).  
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Figure 6:  Surviving MCF-7 colonies after treatment with 6.25, 12.5, and 25 µg/ml 
Photofrin with electroporation, without light treatment. Error bars represent 
standard error of the mean of surviving colonies of triplicate experiments. * : 
difference between indicated sample and control is significant (P≤0.05).  
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Figure 7:  Surviving MCF-7 colonies after treatment with 6.25, 12.5, and 25 µg/ml 
Photofrin with electroporation and exposure to 180 s of 635 nm light at 20 
mW. Error bars represent standard error of the mean of surviving colonies of 
triplicate experiments. * : difference between indicated sample and control is 
significant (P≤0.05). 
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Figure 8:  Surviving MCF-7 colonies after exposure to 60, 120, 180, and 240 s exposure 
to 20 mW, 635 nm laser over 9.6 cm2 wells. Error bars represent standard 
error of the mean of surviving colonies of triplicate experiments. * : difference 
between indicated sample and control is significant (P≤0.05). 
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Figure 9:  Surviving MCF-7 colonies after 60 s exposure to 20 mW, 635 nm laser over 
9.6 cm2 wells with light alone, or light in conjunction with electroporation 
only, 12.5 µg/ml Photofrin only, or both Photofrin and electroporation. Error 
bars represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05). 
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Figure 10:  Surviving MCF-7 colonies after 120 s exposure to 20 mW, 635 nm laser over 
9.6 cm2 wells with light alone, or light in conjunction with electroporation 
only, 12.5 µg/ml Photofrin only, or both Photofrin and electroporation. Error 
bars represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05). †: difference between indicated samples is significant (P>0.05). 
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Figure 11:  Surviving MCF-7 colonies after 180 s exposure to 20 mW, 635 nm laser over 
9.6 cm2 wells with light alone, or light in conjunction with electroporation 
only, 12.5 µg/ml Photofrin only, or both Photofrin and electroporation. Error 
bars represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05). 
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Figure 12:  Surviving MCF-7 colonies after 240 s exposure to 20 mW, 635 nm laser over 
9.6 cm2 wells with light alone, or light in conjunction with electroporation 
only, 12.5 µg/ml Photofrin only, or both Photofrin and electroporation. Error 
bars represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05). 
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Figure 13:  MCF-7 cells were treated with timed exposure to 20 mW, 635 nm laser over 
9.6 cm2 wells with or without electroporation and surviving colonies were 
counted. Error bars represent standard error of the mean of surviving colonies 
of triplicate experiments. * : difference between indicated sample and control 
is significant (P≤0.05). 
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Figure 14:  MCF-7 cells were treated with 12.5 µg/ml Photofrin and indicated timed 
exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or without 
electroporation and surviving colonies were counted. Error bars represent 
standard error of the mean of surviving colonies of triplicate experiments. * : 
difference between indicated sample and control is significant (P≤0.05). 
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Figure 15:  B16-F10 cells were treated with 12.5 µg/ml Photofrin and were subjected to 
indicated timed exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or 
without electroporation and surviving colonies were counted. Error bars 
represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05).
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Figure 16: B16-F10 cells were treated with 12.5 µg/ml Photofrin and were subjected to 
indicated timed exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or 
without electroporation and surviving colonies were counted. Error bars 
represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05).
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Figure 17:  B16-F10 cells were treated with 12.5 µg/ml Photofrin and were subjected to 
indicated timed exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or 
without electroporation and surviving colonies were counted. Error bars 
represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05). †: difference between indicated sample and all other samples is 
significant (P>0.05). 
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Figure 18:  B16-F10 cells were treated with 12.5 µg/ml Photofrin and were subjected to 
indicated timed exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or 
without electroporation and surviving colonies were counted. Error bars 
represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05). †: difference between indicated samples is significant (P>0.05). 
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Figure 19:  B16-F10 cells were treated with 12.5 µg/ml Photofrin and were subjected to 
indicated timed exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or 
without electroporation and surviving colonies were counted. Error bars 
represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05).  
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Figure 20:  B16-F10 cells were treated with 12.5 µg/ml Photofrin and were subjected to 
indicated timed exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or 
without electroporation and surviving colonies were counted. Error bars 
represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05).  
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Figure 21:  B16-F10 cells were treated with 12.5 µg/ml Photofrin and were subjected to 
indicated timed exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or 
without electroporation and surviving colonies were counted. Error bars 
represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05).  
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Figure 22:  B16-F10 cells were treated with 12.5 µg/ml Photofrin and were subjected to 
indicated timed exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or 
without electroporation and surviving colonies were counted. Error bars 
represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05). †: difference between indicated sample and all other samples is 
significant (P>0.05). 
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Figure 23:  B16-F10 cells were treated with 12.5 µg/ml Photofrin and were subjected to 
indicated timed exposure to 20 mW, 635 nm laser over 9.6 cm2 wells with or 
without electroporation and surviving colonies were counted. Error bars 
represent standard error of the mean of surviving colonies of triplicate 
experiments. * : difference between indicated sample and control is significant 
(P≤0.05). †: difference between indicated samples is significant (P>0.05). 
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Figure 24:  MCF-7 cells were stained with acridine orange and imaged with a confocal 
microscope, using an excitation wavelength of 543 nm and a long pass 560 
filter. 
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Figure 25:  MCF-7 cells were exposed to Photofrin and imaged with a confocal 
microscope, using an excitation wavelength of 488 nm and a long pass 505 
filter. 
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Figure 26:  MCF-7 cells were exposed to Photofrin and stained with acridine orange. An 
excitation wavelength of 488 nm was used. Cells were imaged with two 
channels, A) a long pass 505 filter, and B) a band pass 505-560 filter. The two 
channels are superimposed in image C.  
  
60 
 
 
 
 
 
Figure 27:  MCF-7 cells were incubated with Photofrin and then exposed to MitoTracker 
Deep Red, and filtered using a long pass 585 filter.  A) MitoTracker was 
excited with a wavelength of 633 nm, and B) Photofrin was excited with a 
wavelength of 543 nm. Channels are superimposed in image C. 
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Figure 28:  MCF-7 cells were incubated with Photofrin and then exposed to MitoTracker 
Deep Red, and filtered using a long pass 585 filter.  A) MitoTracker was 
excited with a wavelength of 633 nm, and B) Photofrin was excited with a 
wavelength of 543 nm. Channels are superimposed in image C. 
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Figure 29:  B16-F10 cells were exposed to 25 µg/ml Photofrin at a density of 1.0 x 107 
cells/ml and imaged with a confocal microscope, using an excitation 
wavelength of 543 nm and filtered using a long pass 585 filter. 
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Table 1:  Percent MCF-7 cell survival following indicated treatments, where n=3 and P 
value is compared to control samples. Control samples were untreated. 
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Table 2:  Percent MCF-7 cell survival following indicated treatments, where n=3 and P 
value is compared to control samples. Control samples were treated only with 
equivalent amounts of light as treated samples. 
  
65 
 
 
 
 
Table 2:  Percent B16-F10 cell survival following indicated treatments, where n=3 and 
P value is compared to control samples. Control samples were treated only 
with equivalent amounts of light as treated samples. 
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